ライフサイエンスコーパス: disoproxil

1 e increases than those given E/C/F/tenofovir disoproxil fumarate (0.08 vs 0.12 mg/dL; p<0.0001), sign

2 those assigned emtricitabine plus tenofovir disoproxil fumarate (0.48 cases per 100 person-years); H

3 nfidence interval [CI] 0.56-0.96), tenofovir disoproxil fumarate (0.68, 95% CI 0.49-0.95), and lopina

4 que was negatively associated with tenofovir disoproxil fumarate (0.71, 95% CI 0.51-0.99).

5 mg) twice daily and emtricitabine/tenofovir disoproxil fumarate (200/300 mg) once daily.

6 ed (1:1) to receive daily combined tenofovir disoproxil fumarate (245 mg) and emtricitabine (200 mg)

7 were given combination tablets of tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg)

8 gimen of dolutegravir (50 mg) plus tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg).

9 up), or emtricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg) tablets daily, with matched

10 5 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching placebo, onc

11 0 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching placebo.

12 ly or continued therapy containing tenofovir disoproxil fumarate (300 mg).

13 that seen with oral emtricitabine/tenofovir disoproxil fumarate (94.0%; 55.1%-99.2%).

14 ach additional year of exposure to tenofovir disoproxil fumarate (adjusted incidence rate ratio 1.14

15 ir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (combined ART).

16 s were randomized 1:1:1 to receive tenofovir-disoproxil fumarate (DF) plus emtricitabine, and either

17 30 (93%) of 140 patients receiving tenofovir disoproxil fumarate (difference 1.8% [95% CI -3.6 to 7.2

18 e participants switched from E/C/F/tenofovir disoproxil fumarate (E/C/F/TDF 150/150/200/300 mg once d

19 F/tenofovir alafenamide) or 300 mg tenofovir disoproxil fumarate (E/C/F/tenofovir disoproxil fumarate

20 th that of efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF).

21 itegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) with that of efavire

22 TDF) and combination emtricitabine/tenofovir disoproxil fumarate (FTC+TDF), is efficacious for preven

23 combination oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as preexposure prophylaxis

24 (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) decreases the risk of huma

25 round therapies were emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in P007; abacavir/lamivudi

26 xis (PrEP) with emtricitabine plus tenofovir disoproxil fumarate (FTC/TDF) or TDF alone reduces the r

27 % tenofovir (TFV) and oral emtricitabine/TFV disoproxil fumarate (FTC/TDF).

28 al co-formulated emtricitabine and tenofovir disoproxil fumarate (FTC/TDF).

29 neral density than those receiving tenofovir disoproxil fumarate (hip -0.29% [95% CI -0.55 to -0.03]

30 1 occurred in individuals assigned tenofovir disoproxil fumarate (incidence 0.71 cases per 100 person

31 ir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (integrase inhibitor regimen) or rit

32 67 to 200 mg, and 66 to 400 mg) or tenofovir disoproxil fumarate (n=101).

33 mide (n=2694) or emtricitabine and tenofovir disoproxil fumarate (n=2693).

34 r tenofovir alafenamide (n=333) or tenofovir disoproxil fumarate (n=330).

35 fovir alafenamide (n=111 [66%]) or tenofovir disoproxil fumarate (n=56 [34%]).

36 ticipants receiving efavirenz with tenofovir disoproxil fumarate (p=0.001) but not those receiving ef

37 atazanavir with emtricitabine and tenofovir disoproxil fumarate (protease inhibitor based regimen);

38 ustment, persons who had ever used tenofovir disoproxil fumarate (TDF) (1.40; 1.15-1.70) or who were

39 rodrugs - TAF (TAF-based group) or tenofovir disoproxil fumarate (TDF) (TDF-based group) - against th

40 ndomized, pharmacokinetic study of tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200

41 is (PrEP) using the antiretroviral tenofovir disoproxil fumarate (TDF) alone or in combination with e

42 exposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF) and combination emtricitabine/

43 ed to the efavirenz /emtricitabine/tenofovir disoproxil fumarate (TDF) and dolutegravir/emtricitabine

44 Oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are ef

45 assigned to take a combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or pla

46 REP 2139 or REP 2165 combined with tenofovir disoproxil fumarate (TDF) and pegylated interferon alfa-

47 mbinations have been marketed, and tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF

48 In the present study, we show that tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF

49 bine (FTC), rilpivirine (RPV), and tenofovir disoproxil fumarate (TDF) as a 3-drug, single-tablet reg

50 apy currently receive some form of tenofovir disoproxil fumarate (TDF) as part of their HIV treatment

51 100 mg, lamivudine at 300 mg, and tenofovir disoproxil fumarate (TDF) at 300 mg (DOR/3TC/TDF) or to

52 The approved tenofovir disoproxil fumarate (TDF) dose of 300 mg every 48 hours

53 Tenofovir disoproxil fumarate (TDF) has been linked to renal impai

54 ntigen positive patients receiving tenofovir disoproxil fumarate (TDF) in an open-label, longterm ext

55 Despite widespread use of tenofovir disoproxil fumarate (TDF) in pregnant and breastfeeding

56 he efficacy and safety of maternal tenofovir disoproxil fumarate (TDF) in reducing mother-to-infant h

57 Tenofovir disoproxil fumarate (TDF) is active against lamivudine-r

58 Tenofovir disoproxil fumarate (TDF) is an established nucleotide a

59 Tenofovir disoproxil fumarate (TDF) is associated with proximal tu

60 Tenofovir disoproxil fumarate (TDF) is commonly used in antiretrov

61 Tenofovir disoproxil fumarate (TDF) is one of the nucleotide analo

62 Exposure to tenofovir disoproxil fumarate (TDF) may cause renal toxicity.

63 Tenofovir disoproxil fumarate (TDF) plays a pivotal role in antire

64 Clinical studies of systemic tenofovir disoproxil fumarate (TDF) PrEP revealed reduced efficacy

65 ine (FTC) resistance and increased tenofovir disoproxil fumarate (TDF) susceptibility.

66 participants switching from E/C/F/tenofovir disoproxil fumarate (TDF) to E/C/F/TAF.

67 nts with rapid or slow response to tenofovir disoproxil fumarate (TDF) treatment, have been examined

68 blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational

69 Although tenofovir disoproxil fumarate (TDF) use has increased as part of f

70 icistat, emtricitabine (E/C/F) and tenofovir disoproxil fumarate (TDF) who switched to E/C/F and TAF.

71 Replacing tenofovir disoproxil fumarate (TDF) with tenofovir alafenamide (TA

72 ong patients receiving LDV/SOF and tenofovir disoproxil fumarate (TDF) without a protease inhibitor (

73 weeks and combination therapy with tenofovir disoproxil fumarate (TDF) would increase hepatitis D vir

74 Once-daily oral tenofovir disoproxil fumarate (TDF), alone or combined with emtric

75 plus emtricitabine (FTC), MVC plus tenofovir disoproxil fumarate (TDF), and TDF plus FTC.

76 only, MVC-emtricitabine (FTC), MVC-tenofovir disoproxil fumarate (TDF), and TDF-FTC (control).

77 184V/I (0.1%), despite high use of tenofovir disoproxil fumarate (TDF), emtricitabine, and lamivudine

78 fovir and a potential successor of tenofovir disoproxil fumarate (TDF), has been approved in the Unit

79 o assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine

80 strate that a novel gel containing tenofovir disoproxil fumarate (TDF), the more potent prodrug of te

81 (PrEP) with a novel gel containing tenofovir disoproxil fumarate (TDF), the tenofovir prodrug, but no

82 It is unknown if tenofovir disoproxil fumarate (TDF), which is often coformulated w

83 iving with HIV (PLWH) who were receiving TFV disoproxil fumarate (TDF)-based therapy.

84 We compared maraviroc (MVC)- to tenofovir disoproxil fumarate (TDF)-containing ART.

85 of renal and endocrine changes in tenofovir disoproxil fumarate (TDF)-related bone toxicity.

86 e clinically approved formulation, tenofovir disoproxil fumarate (TDF).

87 ficacy of oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF).

88 sons living with HIV (PLWH) taking tenofovir disoproxil fumarate (TDF).

89 ital admission by use of the NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir

90 PLWH receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/EFV 600 mg

91 ymptomatic HSV-2 infection to oral tenofovir disoproxil fumarate (TDF)/placebo vaginal gel, oral plac

92 signed to groups given either oral tenofovir disoproxil fumarate (TDF, 300 mg) and placebo (n = 64) o

93 Tenofovir disoproxil fumarate (tenofovir) has been associated with

94 e inhibitor and emtricitabine plus tenofovir disoproxil fumarate (tenofovir) regimen to coformulated

95 .01 mg/dL [95% CI 0.00 to 0.02] vs tenofovir disoproxil fumarate 0.02 mg/dL [0.00 to 0.04], adjusted

96 r alafenamide 40 [14%] patients vs tenofovir disoproxil fumarate 14 [10%] patients), nasopharyngitis

97 -daily oral fixed-dose combination tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg, and

98 or 400 mg once a day or to receive tenofovir disoproxil fumarate 300 mg once a day; each allocation w

99 of tenofovir alafenamide 25 mg or tenofovir disoproxil fumarate 300 mg, each with matching placebo.

100 r (RTV) or standard of care (SOC) (tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and AT

101 ily oral fixed-dose combination of tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and ef

102 e DOR groups (DOR/lamivudine [3TC]/tenofovir disoproxil fumarate [TDF] or DOR [100 mg daily] with emt

103 gnificantly different from that of tenofovir disoproxil fumarate alone (hazard ratio [HR] 0.67, 95% C

104 ficacy of daily oral emtricitabine-tenofovir disoproxil fumarate among HIV-seronegative men and trans

105 h noncalcified/mixed plaque, while tenofovir disoproxil fumarate and efavirenz were negatively associ

106 Daily, oral use of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) for pree

107 and Drug Safety in Korea approved tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) co-formu

108 reexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine (Truvada) has demo

109 l fumarate monotherapy or combined tenofovir disoproxil fumarate and emtricitabine and whether the be

110 a context that also includes oral tenofovir disoproxil fumarate and emtricitabine as an option.

111 he new product in addition to oral tenofovir disoproxil fumarate and emtricitabine as compared with o

112 e-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine for the prevention

113 sure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine in 2499 men who ha

114 osted atazanavir plus coformulated tenofovir disoproxil fumarate and emtricitabine once a day (atazan

115 ir/ritonavir and 2 nucleos(t)ides (tenofovir disoproxil fumarate and emtricitabine or abacavir and la

116 let) orally twice daily, each with tenofovir disoproxil fumarate and emtricitabine orally once daily,

117 -group phase 3 trial of daily oral tenofovir disoproxil fumarate and emtricitabine plus tenofovir dis

118 n, the protective efficacy of oral tenofovir disoproxil fumarate and emtricitabine relies on optimal

119 olour), and lamivudine tablets and tenofovir disoproxil fumarate and emtricitabine tablets were over-

120 earance and the number of doses of tenofovir disoproxil fumarate and emtricitabine taken per week, as

121 e-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine was adopted by WHO

122 hey are non-inferior to daily oral tenofovir disoproxil fumarate and emtricitabine.

123 ts started RAL in combination with tenofovir disoproxil fumarate and lamivudine after initiation of R

124 less renal and bone toxicity than tenofovir disoproxil fumarate and might improve the long-term safe

125 In contrast, tenofovir disoproxil fumarate and tenofovir alafenamide conferred

126 In contrast, tenofovir disoproxil fumarate and tenofovir alafenamide treatment

127 We quantified tenofovir disoproxil fumarate and tenofovir concentrations in cerv

128 01 had similar efficacy to that of tenofovir disoproxil fumarate and was associated with a smaller de

129 to combination emtricitabine plus tenofovir disoproxil fumarate as PrEP.

130 xil fumarate or emtricitabine plus tenofovir disoproxil fumarate as PrEP.

131 target cells more efficiently than tenofovir disoproxil fumarate at a lower dose, thereby reducing sy

132 atients who started treatment with tenofovir disoproxil fumarate at a public hospital in Ethiopia bet

133 oral PrEP with emtricitabine plus tenofovir disoproxil fumarate at a research centre in Cape Town, S

134 Tenofovir disoproxil fumarate can cause renal and bone toxic effec

135 against vaginal challenge similar to FTC/TFV disoproxil fumarate combination in the macaque model.

136 ir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate compared with a boosted protease inh

137 PrEP with oral emtricitabine plus tenofovir disoproxil fumarate compared with placebo in men who hav

138 fumarate; one patient assigned to tenofovir disoproxil fumarate did not receive the treatment.

139 ide and 12 (4%) patients receiving tenofovir disoproxil fumarate experienced serious adverse events,

140 luded traditional risk factors and tenofovir disoproxil fumarate exposure.

141 ad been on daily emtricitabine and tenofovir disoproxil fumarate for 8 months presented with fever, u

142 ) on efavirenz, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months before enrolme

143 on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months before enrolme

144 fficacy to daily emtricitabine and tenofovir disoproxil fumarate for HIV prevention, and the number o

145 non-inferior to emtricitabine and tenofovir disoproxil fumarate for HIV prevention, as the upper lim

146 afenamide versus emtricitabine and tenofovir disoproxil fumarate for HIV prevention.

147 and 93% for the emtricitabine plus tenofovir disoproxil fumarate group (0.07, 0.02-0.23; p<0.0001).

148 ticipants in the emtricitabine and tenofovir disoproxil fumarate group (0.34 infections per 100 perso

149 p and in 444 (93%) assigned to the tenofovir disoproxil fumarate group (adjusted difference 4.1%, 95%

150 ide group and -0.10% (3.39) in the tenofovir disoproxil fumarate group (between-group difference 2.43

151 oup compared with 307 (93%) in the tenofovir disoproxil fumarate group (difference 1.3%, 95% CI -2.5

152 ide group and -0.73% (3.21) in the tenofovir disoproxil fumarate group (difference 2.04% [1.17-2.90];

153 ction in HIV-1 acquisition for the tenofovir disoproxil fumarate group (HR 0.15, 95% CI 0.06-0.37; p<

154 ompared with 88 (89%) of 99 in the tenofovir disoproxil fumarate group (modified intention-to-treat p

155 tudy treatment; one patient in the tenofovir disoproxil fumarate group died, but this was not deemed

156 enamide (2%) and three (1%) in the tenofovir disoproxil fumarate group discontinued due to adverse ev

157 up and one (2%) participant in the tenofovir disoproxil fumarate group had an adverse event that was

158 nd 96 (33%) of 292 patients in the tenofovir disoproxil fumarate group had grade 3 or 4 laboratory ab

159 d thrombocytopenia) and two in the tenofovir disoproxil fumarate group had study drug-related serious

160 d 784 (90%) of 867 patients in the tenofovir disoproxil fumarate group having plasma HIV-1 RNA less t

161 oxil fumarate-containing regimens (tenofovir disoproxil fumarate group) for 96 weeks.

162 r alafenamide group and 314 to the tenofovir disoproxil fumarate group).

163 ticipants in the emtricitabine and tenofovir disoproxil fumarate group).

164 placebo tablets (emtricitabine and tenofovir disoproxil fumarate group).

165 enamide group; and one (2%) in the tenofovir disoproxil fumarate group).

166 the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group.

167 r alafenamide group and 477 to the tenofovir disoproxil fumarate group.

168 e group compared with those in the tenofovir disoproxil fumarate group.

169 and arthralgia (four [7%]) in the tenofovir disoproxil fumarate group.

170 mpared with 37 (12%) of 314 in the tenofovir disoproxil fumarate group; none of these were serious.

171 lafenamide and 294 (94%) of 313 on tenofovir disoproxil fumarate had maintained less than 50 copies p

172 e and nine (6%) patients receiving tenofovir disoproxil fumarate had serious adverse events, none of

173 C/F/tenofovir alafenamide or E/C/F/tenofovir disoproxil fumarate had virological success.

174 Antiretroviral regimens containing tenofovir disoproxil fumarate have been associated with renal toxi

175 was superior to emtricitabine and tenofovir disoproxil fumarate in all six prespecified bone mineral

176 study of rilpivirine/emtricitabine/tenofovir disoproxil fumarate in ART-naive HIV controllers (N = 35

177 l tenofovir disoproxil fumarate or tenofovir disoproxil fumarate in combination with emtricitabine, h

178 inuing rilpivirine, emtricitabine, tenofovir disoproxil fumarate in maintaining viral suppression and

179 cy and safety of BMS-986001 versus tenofovir disoproxil fumarate in treatment-naive patients with HIV

180 PrEP with oral emtricitabine plus tenofovir disoproxil fumarate in women.

181 cokinetics, and acceptability of a tenofovir disoproxil fumarate intravaginal ring used continuously

182 Emtricitabine with tenofovir disoproxil fumarate is a standard-of-care nucleoside rev

183 However, tenofovir disoproxil fumarate is associated with renal and bone to

184 axis (PrEP) with emtricitabine and tenofovir disoproxil fumarate is highly effective against acquisit

185 Daily emtricitabine/tenofovir disoproxil fumarate is recommended as preexposure prophy

186 (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate is used to prevent the sexual acquis

187 vention of HIV infection with oral tenofovir disoproxil fumarate monotherapy or combined tenofovir di

188 k of HIV infection, PrEP with oral tenofovir disoproxil fumarate monotherapy or tenofovir disoproxil

189 tegravir twice daily and 300 mg of tenofovir disoproxil fumarate once daily as a backbone.

190 tase inhibitors: emtricitabine and tenofovir disoproxil fumarate or abacavir and lamivudine.

191 12 among patients receiving either tenofovir disoproxil fumarate or abacavir as part of their antiret

192 followed; adjustment should avoid tenofovir disoproxil fumarate or boosted protease inhibitors in at

193 rerandomisation in a 1:1 ratio to tenofovir disoproxil fumarate or emtricitabine plus tenofovir diso

194 ined with emtricitabine and either tenofovir disoproxil fumarate or tenofovir alafenamide), with a th

195 rophylaxis (PrEP), with daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fumarate in

196 Second, the effectiveness of tenofovir disoproxil fumarate plus emtricitabine varies across pop

197 rEP), using daily oral combination tenofovir disoproxil fumarate plus emtricitabine, is an effective

198 xposure by the third daily dose of tenofovir disoproxil fumarate plus emtricitabine.

199 ew PrEP agent or oral coformulated tenofovir disoproxil fumarate plus emtricitabine.

200 study of daily oral emtricitabine-tenofovir disoproxil fumarate PrEP among 50 HIV-uninfected breastf

201 il fumarate and emtricitabine plus tenofovir disoproxil fumarate PrEP in HIV-1 uninfected individuals

202 d 402 (92%) of 437 assigned to the tenofovir disoproxil fumarate regimen (difference -2.0%, 95.001% C

203 dose of study drug and were on the tenofovir disoproxil fumarate regimen before screening were includ

204 essed the efficacy of single-agent tenofovir disoproxil fumarate relative to combination emtricitabin

205 12 were assigned to receive the tenofovir disoproxil fumarate ring and five were assigned to recei

206 d 28 compared with baseline in the tenofovir disoproxil fumarate ring group but not the placebo group

207 Two participants in the tenofovir disoproxil fumarate ring group completed 3 months of con

208 dverse events were reported in the tenofovir disoproxil fumarate ring group.

209 of ulcerations is specific to this tenofovir disoproxil fumarate ring or generalisable to other susta

210 were randomly assigned (3:1) to a tenofovir disoproxil fumarate ring or placebo ring.

211 witching from a regimen containing tenofovir disoproxil fumarate to elvitegravir, cobicistat, emtrici

212 switching from emtricitabine with tenofovir disoproxil fumarate to emtricitabine with tenofovir alaf

213 witching from a regimen containing tenofovir disoproxil fumarate to one containing tenofovir alafenam

214 were independent of emtricitabine/tenofovir disoproxil fumarate use.

215 r alafenamide to emtricitabine and tenofovir disoproxil fumarate was established if the upper bound o

216 aining regimen from one containing tenofovir disoproxil fumarate was non-inferior for maintenance of

217 from efavirenz, emtricitabine, and tenofovir disoproxil fumarate was non-inferior in maintaining vira

218 n efficacy with emtricitabine plus tenofovir disoproxil fumarate was not significantly different from

219 use of PrEP with emtricitabine and tenofovir disoproxil fumarate were not excluded.

220 enal and bone safety compared with tenofovir disoproxil fumarate when used for HIV treatment.

221 he 195 (67%) of patients receiving tenofovir disoproxil fumarate who had HBV DNA less than 29 IU/mL (

222 mg tenofovir alafenamide or 300 mg tenofovir disoproxil fumarate with matching placebo.

223 36 [13%] of 288 patients receiving tenofovir disoproxil fumarate) and AST (20 [3%] of 577 patients re

224 nz combined with emtricitabine and tenofovir disoproxil fumarate) previously recommended by WHO.

225 on cART (predominantly containing tenofovir disoproxil fumarate) were also more likely to experience

226 nofovir disoproxil fumarate (E/C/F/tenofovir disoproxil fumarate) with matching placebo.

227 22 [8%] of 292 patients receiving tenofovir disoproxil fumarate), nasopharyngitis (56 [10%] vs 16 [5

228 437 with efavirenz, emtricitabine, tenofovir disoproxil fumarate).

229 regimens include emtricitabine and tenofovir disoproxil fumarate).

230 tenofovir alafenamide and 292 with tenofovir disoproxil fumarate).

231 19 [7%] of 288 patients receiving tenofovir disoproxil fumarate).

232 ir alafenamide and 867 given E/C/F/tenofovir disoproxil fumarate).

233 ation emtricitabine, 200 mg/d, and tenofovir disoproxil fumarate, 300 mg/d.

234 ociated with more weight gain than tenofovir disoproxil fumarate, abacavir, or zidovudine.

235 LA, 6 received oral emtricitabine/tenofovir disoproxil fumarate, and 10 were untreated.

236 therapy (ART; combined efavirenz, tenofovir disoproxil fumarate, and emtricitabine).

237 namide was non-inferior to that of tenofovir disoproxil fumarate, and had improved bone and renal eff

238 ir alafenamide was non-inferior to tenofovir disoproxil fumarate, and had improved bone and renal eff

239 than a standard regimen containing tenofovir disoproxil fumarate, and might be a treatment option for

240 5 (78%) of 351 participants in the tenofovir disoproxil fumarate, emtricitabine, and dolutegravir gro

241 egravir group; 4.3 kg [6.7] in the tenofovir disoproxil fumarate, emtricitabine, and dolutegravir gro

242 and dolutegravir group, 351 to the tenofovir disoproxil fumarate, emtricitabine, and dolutegravir gro

243 infants exposed from conception to tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TDF-F

244 8 (74%) of 351 participants in the tenofovir disoproxil fumarate, emtricitabine, and efavirenz group

245 en (3%) of 351 participants in the tenofovir disoproxil fumarate, emtricitabine, and efavirenz group

246 vir group, and 2.3 kg [7.0] in the tenofovir disoproxil fumarate, emtricitabine, and efavirenz group)

247 dolutegravir group, and 351 to the tenofovir disoproxil fumarate, emtricitabine, and efavirenz group.

248 Compared with tenofovir disoproxil fumarate, individuals in the BMS-986001 group

249 trovirals abacavir sulphate (ABC), tenofovir disoproxil fumarate, or tenofovir alafenamide.

250 at releases the tenofovir prodrug, tenofovir disoproxil fumarate, provided 100% protection in macaque

251 one (1%) of 99 patients receiving tenofovir disoproxil fumarate, respectively.

252 itonavir, lopinavir/ritonavir, and tenofovir disoproxil fumarate, respectively.

253 d for up to 6 years of exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazanavir, or ri

254 ciated with cumulative exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazanavir, riton

255 oncentrations by 90% compared with tenofovir disoproxil fumarate, thereby decreasing bone and renal r

256 e efficiently at a lower dose than tenofovir disoproxil fumarate, thereby reducing systemic exposure.

257 mtricitabine with 200 mg or 300 mg tenofovir disoproxil fumarate, while remaining on the same third a

258 fenamide was non-inferior to E/C/F/tenofovir disoproxil fumarate, with 800 (92%) of 866 patients in t

259 alafenamide was as efficacious as tenofovir disoproxil fumarate, with reduced bone and renal toxic e

260 EMP had greater TF activity, while tenofovir disoproxil fumarate- and tenofovir alafenamide-treated c

261 to HIV-negative individuals using tenofovir disoproxil fumarate-based pre-exposure prophylaxis for t

262 itude of benefit of PrEP with oral tenofovir disoproxil fumarate-based therapy to reduce the risk of

263 arly all (97.6%) patients received tenofovir disoproxil fumarate-containing ART, in line with nationa

264 mL), aged 60 years or older, on a tenofovir disoproxil fumarate-containing regimen and were randomly

265 rry on taking one of four previous tenofovir disoproxil fumarate-containing regimens (tenofovir disop

266 eater, and were taking one of four tenofovir disoproxil fumarate-containing regimens for at least 96

267 enal and bone safety compared with tenofovir disoproxil fumarate-containing regimens.

268 and potentially safer option than tenofovir disoproxil fumarate-emtricitabine (F/TDF) for HIV preexp

269 cipants were randomized to receive tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) plus atazana

270 importance of expanding access to tenofovir disoproxil fumarate-sparing regimens in resource-limited

271 n of enrollment, hypertension, and tenofovir disoproxil fumarate.

272 ease inhibitor, emtricitabine, and tenofovir disoproxil fumarate.

273 ated efavirenz, emtricitabine, and tenofovir disoproxil fumarate.

274 onsistent use of emtricitabine and tenofovir disoproxil fumarate.

275 iority of tenofovir alafenamide to tenofovir disoproxil fumarate.

276 on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate.

277 atazanavir with emtricitabine and tenofovir disoproxil fumarate.

278 those remaining on one containing tenofovir disoproxil fumarate.

279 enofovir alafenamide compared with tenofovir disoproxil fumarate.

280 enal and bone safety compared with tenofovir disoproxil fumarate.

281 s switched from emtricitabine with tenofovir disoproxil fumarate.

282 tiation of efavirenz/emtricitabine/tenofovir disoproxil fumarate.

283 onavir, or efavirenz/emtricitabine/tenofovir disoproxil fumarate.

284 enal safety than emtricitabine and tenofovir disoproxil fumarate.

285 l studies using oral emtricitabine-tenofovir disoproxil fumarate.

286 tudy estimated the number of daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) doses requir

287 PrEP) interventions worldwide, yet tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for PrEP is

288 individuals randomized equally to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) plus atazana

289 virologically suppressed on tenofovir (TFV) disoproxil fumarate/emtricitabine and ritonavir-boosted

290 ion as the number of people taking tenofovir disoproxil fumarate/emtricitabine for HIV prevention.

291 Daily tenofovir disoproxil fumarate/emtricitabine is recommended for use

292 ve participants were randomized to tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritona

293 bone mineral density (BMD) during tenofovir disoproxil fumarate/emtricitabine preexposure prophylaxi

294 disoproxil fumarate monotherapy or tenofovir disoproxil fumarate/emtricitabine was associated with de

295 ors (NRTIs; abacavir/lamivudine or tenofovir disoproxil fumarate/emtricitabine) and a third single or

296 mpala, Uganda, and receiving daily tenofovir disoproxil fumarate/lamivudine were recruited.

297 ir alafenamide and 141 assigned to tenofovir disoproxil fumarate; one patient assigned to tenofovir d

298 prophylaxis (PrEP) in the form of tenofovir-disoproxil-fumarate/emtricitabine is being implemented i

299 ose combination emtricitabine with tenofovir disoproxil fumartate from 78 sites in North America and

300 , participants received daily oral tenofovir disoproxil fumurate and emtricitabine for HIV PrEP, quar